Elad Jacoby

List of Publications by Year
in descending order

66 papers	3,457 citations	361296 20 h-index	182361 51 g-index
67 all docs	67 docs citations	67 times ranked	5172 citing authors

#	Article	IF	Citations
1	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	7.7	997
2	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nature Communications, 2016, 7, 12320.	5.8	325
3	Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplantation, 2019, 54, 1643-1650.	1.3	254
4	MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget, 2013, 4, 665-676.	0.8	181
5	MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. Journal of Clinical Investigation, 2013, 123, 2703-2718.	3.9	149
6	TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Science Translational Medicine, 2017, 9, .	5.8	136
7	Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. Frontiers in Immunology, 2020, 11, 1347.	2.2	135
8	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
9	MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor. PLoS ONE, 2013, 8, e54652.	1.1	94
10	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. American Journal of Hematology, 2018, 93, 1485-1492.	2.0	93
11	Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood, 2016, 127, 1361-1370.	0.6	87
12	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
13	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
14	Challenges and opportunities of allogeneic donor-derived CAR T cells. Current Opinion in Hematology, 2015, 22, 509-515.	1.2	81
15	Updates on CAR Tâ€cell therapy in Bâ€cell malignancies. Immunological Reviews, 2019, 290, 39-59.	2.8	61
16	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
17	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigenâ€“Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 112-118.	2.0	37
18	The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplantation, 2019, 54, 810-814.	1.3	33

#	Article	IF	Citations
19	Murine Models of Acute Leukemia: Important Tools in Current Pediatric Leukemia Research. Frontiers in Oncology, 2014, 4, 95.	1.3	31
20	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. Journal of the National Cancer Institute, 2022, 114, 436-445.	3.0	29
21	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia, 2022, 36, 1525-1532.	3.3	27
22	CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transplantation, 2018, 53, 1583-1585.	1.3	25
23	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Current Research in Translational Medicine, 2020, 68, 17-22.	1.2	24
24	Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. , 2021, 9, e001743.		23
25	Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric Bâ€cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. Pediatric Blood and Cancer, 2019, 66, e27898.	0.8	22
26	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leukemia and Lymphoma, 2021, 62, 1692-1701.	0.6	22
27	Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways. Blood Advances, 2017, 1, 1749-1759.	2.5	19
28	Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. Transfusion and Apheresis Science, 2020, 59, 102769.	0.5	19
29	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 1134-1143.	1.3	17
30	Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade Glioma. World Neurosurgery, 2019, 130, e324-e332.	0.7	15
31	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. Clinical Hematology International, 2019, 1, 79.	0.7	15
32	Mitochondrial augmentation of CD34+ cells from healthy donors and patients with mitochondrial DNA disorders confers functional benefit. Npj Regenerative Medicine, 2021, 6, 58.	2.5	15
33	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplantation and Cellular Therapy, 2022, 28, 251-257.	0.6	14
34	Comparison of two cytoreductive regimens for Î±Î²â€Tâ€cellâ€depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBIâ€based regimen. Pediatric Blood and Cancer, 2018, 65, e26839.	0.8	12
35	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. Leukemia, 2020, 34, 1939-1942.	3.3	12
36	Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. Blood, 2019, 134, 3234-3234.	0.6	12

#	Article	IF	Citations
37	Carina Angle Measurements for Diagnosis of Patent Ductus Arteriosus in Preterm Infants. Neonatology, 2011, 99, 224-230.	0.9	10
38	Parameters of longâ€term response with <scp>CD28</scp>â€based <scp>CD19 chimaeric antigen receptorâ€modified</scp> T cells in children and young adults with <scp>Bâ€acute lymphoblastic leukaemia</scp>. British Journal of Haematology, 2022, 197, 475-481.	1.2	10
39	The Effect of Prolonged Physical Activity Performed during Extreme Caloric Deprivation on Cardiac Function. PLoS ONE, 2012, 7, e31266.	1.1	9
40	Related to testes-specific, vespid and pathogenesis protein-1 is regulated by methylation in glioblastoma. Oncology Letters, 2014, 7, 1209-1212.	0.8	9
41	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. Cells, 2022, 11, 1140.	1.8	8
42	First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome. Blood, 2018, 132, 1024-1024.	0.6	7
43	Haploidentical hematopoietic stem cell transplantation with Î±Î²TCR+/CD19+ depletion in pediatric patients with malignant and non-malignant disorders. Bone Marrow Transplantation, 2019, 54, 694-697.	1.3	6
44	Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. Bone Marrow Transplantation, 2021, 56, 2248-2258.	1.3	6
45	CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells. Blood, 2015, 126, 100-100.	0.6	6
46	Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR. Blood, 2015, 126, 2524-2524.	0.6	6
47	Improved transplant outcomes with myeloablative conditioning for hemophagocytic lymphohistiocytosis in HLA-matched and mismatched donors: a national multicenter retrospective study. Bone Marrow Transplantation, 2021, 56, 2088-2096.	1.3	5
48	Neonatal Hyperpigmentation: Diagnosis of Familial Glucocorticoid Deficiency with a Novel Mutation in the Melanocortinâ€2 Receptor Gene. Pediatric Dermatology, 2014, 31, e13-7.	0.5	3
49	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3824-3824.	0.6	3
50	Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement. Blood, 2020, 136, 1-1.	0.6	2
51	Donor assessment and follow-up: not a minor issue. Bone Marrow Transplantation, 2019, 54, 1728-1729.	1.3	1
52	Senescent/Exhausted Phenotype of CAR T Cells and Induction of Immunoregulatory Environment Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, S314-S315.	2.0	1
53	Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a Bridge to Immunotherapy. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.3	1
54	CRLF2 /Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells. Blood, 2015, 126, 1432-1432.	0.6	1

#	Article	IF	Citations
55	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. Blood, 2021, 138, 910-910.	0.6	1
56	Adult Acute Lymphoblastic Leukaemia. , 2022, , 61-66.		1
57	Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia. , 2019, , 127-140.		0
58	CAR 2.0: The Next Generation of Synthetic Receptorâ€"Based Cellular Therapy for Cancer. , 2020, , 199-208.		0
59	CAR T cells for the long run in aggressive B-cell lymphoma. Lancet Oncology, The, 2021, 22, 1347-1348.	5.1	0
60	Anterior chamber infiltration of CAR T-cells. American Journal of Ophthalmology Case Reports, 2021, 24, 101223.	0.4	0
61	41BBL-Based Activation and Expansion of Autologous Natural Killer Cells Results in Enhanced Activity Against Leukemia Including ALL. Blood, 2014, 124, 2293-2293.	0.6	0
62	CD19 CAR T Cells Maintain Efficacy in the Allogeneic Environment but Mediate Acute Graft-Versus-Host-Disease Only in the Presence CD19+ Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1115-1115.	0.6	0
63	Presence of Endogenous TCR Antigen in Vivo Attenuates Efficacy of Anti-CD19 Targeted CAR T Cell Therapy. Blood, 2014, 124, 3721-3721.	0.6	0
64	In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients. Blood, 2020, 136, 15-16.	0.6	0
65	The Phenotypic, Transcriptional and Functional Properties of CAR T Cells Products May Predict Response of Patients with B Cell Lymphoid Malignancies Treated with CD19 CAR-T Cells. Transplantation and Cellular Therapy, 2022, 28, S166.	0.6	0
66	Durable Remissions of Refractory Lymphoma in Patients with Underlying Immunodeficiencies Treated with Allogeneic HSCT. Transplantation and Cellular Therapy, 2022, 28, S414.	0.6	0